SOUL is a large randomized trial of oral semaglutide in adults with type 2 diabetes and established cardiovascular or kidney disease. In this Hormone Insight clinical evidence discussion, we cover the five-part PICO, the primary MACE result, absolute event rates, the non-significant kidney secondary outcome, patient selection, and limits of generalization. Fahad narration, clean voice-only production, no music. Primary source: PMID 40162642. DOI 10.1056/NEJMoa2501006. For healthcare professionals. This episode is an evidence discussion, not a substitute for the original paper, product information, local guidance, or individualized clinical judgment.

Can once-weekly semaglutide produce meaningful weight loss in adults with obesity?

In this 2-minute evidence brief, we break down the STEP 1 trial, a randomized double-blind clinical trial published in the New England Journal of Medicine in 2021. The study tested semaglutide 2.4 mg once weekly versus placebo, both with lifestyle intervention, in adults with overweight or obesity but without diabetes.

Covered in this video:

• Why the STEP 1 trial was done
• How the trial was conducted
• Main weight loss results
• Safety and gastrointestinal side effects
• Key clinical takeaway
• 
  

Main result: average body weight decreased by 14.9% with semaglutide versus 2.4% with placebo over 68 weeks.

Citation:

Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

PMID: 33567185

DOI: 10.1056/NEJMoa2032183

This video is for medical education only and does not replace clinical judgment or individual medical advice.

#Semaglutide #STEP1Trial #ObesityMedicine #GLP1 #MedicalEducation

semaglutide, STEP 1 trial, semaglutide obesity, semaglutide weight loss, Wegovy, GLP-1 receptor agonist, obesity treatment, obesity medicine, clinical trial explained, randomized controlled trial, RCT, NEJM, weight loss medication, semaglutide 2.4 mg, evidence based medicine, medical education, endocrinology, hormone insight, GLP-1 weight loss, obesity pharmacotherapy

This week on Hormone Insight: the fallout from the ADA 2026 Scientific Sessions, where retatrutide — a triple GIP/GLP-1/glucagon agonist — delivered nearly 2 points of A1C and about 15% weight loss in type 2 diabetes (TRANSCEND-T2D-1). Plus CagriSema vs semaglutide head-to-head, finerenone in chronic kidney disease without diabetes, the new ADA/EASD type 1 diabetes consensus, and a Hormone Classic revisit of SUSTAIN-6 — the outcome bar every new drug still has to clear.

Segments:

• Trial of the Week — Retatrutide in type 2 diabetes (TRANSCEND-T2D-1, The Lancet)

• Quick Hit 1 — CagriSema vs semaglutide (REIMAGINE 2, Lancet Diabetes & Endocrinology)

• Quick Hit 2 — Finerenone in CKD without diabetes (FIND-CKD, NEJM)

• Guideline & FDA Watch — ADA/EASD type 1 diabetes in adults: 2026 consensus update

• Hormone Classic — SUSTAIN-6 (semaglutide cardiovascular outcomes, 2016)

⏱ Chapters

00:00 Cold open

00:38 Welcome & disclaimer

01:02 This week

01:47 Trial of the Week — Retatrutide (TRANSCEND-T2D-1)

03:51 The Appraisal

04:59 Bottom line — retatrutide

05:29 Quick Hit 1 — CagriSema vs semaglutide

06:54 Quick Hit 2 — Finerenone in CKD without diabetes

08:04 Guideline & FDA Watch — ADA/EASD type 1 diabetes

09:20 Hormone Classic — SUSTAIN-6

10:40 The Bottom Line

11:23 Sign-off

References & written summary: hormoneinsight.com/twide-2026-06-27

For healthcare professionals. Educational, not individual medical advice.

Subscribe for a new episode every Saturday. #diabetes #endocrinology #GLP1

This week on This Week in Diabetes & Endocrinology, from Hormone Insight: the

first large phase 3 trial of an oral GLP-1, orforglipron, in adults with type 2

diabetes and obesity (ATTAIN-2, Lancet). The headline is not the size of the

weight loss. It is the word oral.

Also this week:

- A 112,000-patient ACP network meta-analysis that keeps semaglutide and

tirzepatide on top for both weight loss and cardiovascular outcomes

- A provocative real-world comparison of bariatric surgery versus semaglutide

in fatty liver disease

- The 2026 ADA Standards of Care, which make cardiovascular and kidney

protection a co-primary goal alongside A1C

- A Hormone Classic revisit of UKPDS that explains why that shift had to happen

One question runs through all of it: does this change Monday clinic?

Chapters

00:00 Cold open

00:42 This week

01:13 Trial of the Week: orforglipron (ATTAIN-2)

04:29 Quick Hit: ACP weight-loss drug meta-analysis

05:21 Quick Hit: surgery vs semaglutide (MASLD)

06:21 Guideline & FDA Watch: 2026 ADA Standards

07:27 Hormone Classics: UKPDS

08:26 The Bottom Line

08:57 Sign-off

References and written summary: hormoneinsight.com/[slug]

For healthcare professionals. Educational, not individual medical advice.

Subscribe for a new episode every Saturday.

#diabetes #endocrinology #GLP1 #obesity #ADA2026

Oral Ozempic Launch, Semaglutide for Alcohol Use Disorder (Lancet RCT), and Canada’s First Generic Semaglutide | Week Ending May 8, 2026

This short Week in Diabetes and Endocrinology update covers three key developments for the week ending May 8, 2026: the nationwide U.S. launch of Oral Ozempic (rebranded/reformulated oral semaglutide tablets in 1.5, 4, and 9 mg with smaller pill size, same efficacy/safety, and cardiovascular risk-reduction labeling for adults with type 2 diabetes and established cardiovascular disease, plus pricing details and ongoing fasting administration requirements); a Lancet 26-week randomized trial in 108 adults with obesity and moderate-to-severe alcohol use disorder showing once-weekly semaglutide 2.4 mg added to CBT reduced heavy drinking days and total alcohol consumption with substantial weight loss, while noting it is not approved for AUD and was studied only in obese participants; and Health Canada’s approval of Apotex’s Apo-Semaglutide injection as the first Canadian-made generic Ozempic equivalent, signaling shifting global GLP-1 pricing and access.

00:00 Weekly Headlines

00:24 Oral Ozempic Launch

00:59 Dosing Labeling Pricing

01:45 Lancet AUD Trial

02:29 What It Means Clinically

03:02 Limits Next Trials

03:33 Canada Generic Semaglutide

04:08 Global Access Shift

04:34 Wrap Up And Sign Off

This episode reviews key diabetes/endocrinology updates for the week ending May 1, 2026: FDA clearance of Tandem Control-IQ Plus automated insulin delivery for pregnancy in type 1 diabetes supported by the CIRCUIT trial showing improved pregnancy-specific time-in-range; a US cost-effectiveness analysis in type 2 diabetes finding tirzepatide 10 mg and 15 mg cost-effective vs semaglutide 2 mg (ICERs ≈$70,147 and ≈$54,699 per QALY); late-breaking AACE meeting signals across obesity (combination therapies), thyroid ultrasound findings, and access disparities; a meta-analysis showing dapagliflozin increases hemoglobin in CKD; why most hypoglycemia risk prediction models in type 2 diabetes aren’t clinic-ready; and a trial where a short calorie-restricted high-dose oat diet lowered zonulin and increased butyric acid in metabolic syndrome.

00:00 Weekly Overview

01:07 FDA AID Pregnancy

04:14 Tirzepatide Value Math

06:39 AACE Meeting Signals

08:48 SGLT2 Anemia Boost

11:23 Hypoglycemia Prediction Reality

13:16 Oats Gut Barrier Pearl

15:29 Wrap Up and Notes

The Week in Diabetes & Endocrinology — Episode 004 | April 24, 2026

From Hormone Insight (hormoneinsight.com)

Six stories this week that endocrinologists, diabetologists, and internists need to know.

TIMESTAMPS:

0:00 — Introduction & This Week's Stories

1:15 — Tzield (Teplizumab) FDA Expanded to Age 1+ for Stage 2 Type 1 Diabetes

5:30 — AACE 2026 Annual Meeting in Las Vegas: What's Worth Watching

8:30 — Orforglipron ATTAIN-1 Subgroup: Consistent Weight Loss Across Every BMI

12:00 — First Generic Dapagliflozin Arrives: Cost and Access Implications

15:00 — GLP-1 Receptor Agonists and Erectile Dysfunction: Signal or Noise?

18:00 — AACE Thyroid Ultrasound Finding: A New Clue for Indeterminate Nodules

20:00 — Closing Thoughts

REFERENCES & SHOW NOTES:

▸ Tzield (teplizumab-mzwv) sBLA FDA approval: https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650

▸ AACE 2026 Annual Meeting, Las Vegas (April 22–24): https://pro.aace.com

▸ Orforglipron ATTAIN-1 BMI subgroup (AACE 2026): https://www.endocrinologyadvisor.com/reports/orforglipron-weight-loss-bmi-categories/

▸ First generic dapagliflozin FDA approval: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets

▸ GLP-1 RA and erectile dysfunction target-trial emulation (eClinicalMedicine): https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00104-5/fulltext

▸ AACE thyroid ultrasound presentation (post-microcystic reflection in indeterminate nodules)

ABOUT THIS PODCAST:

A weekly evidence-based review of the top stories in diabetes, obesity, thyroid, and endocrinology — modeled on Medscape's "This Week in Cardiology." New episodes every Thursday. For healthcare professionals.

▸ Website: https://hormoneinsight.com

▸ Full show notes: https://hormoneinsight.com/podcast

DOWNLOAD THE APP:

▸ iOS: https://apps.apple.com/dz/app/hormone-insight/id6749515856

▸ Android: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl

️ This content is intended for healthcare professionals. It does not constitute medical advice for patients.

#Endocrinology #DiabetesResearch #Tzield #Teplizumab #Type1Diabetes #AACE2026 #Orforglipron #GLP1 #Dapagliflozin #Farxiga #SGLT2 #ErectileDysfunction #ThyroidNodule #Endocrinology #ObesityMedicine #MedicalPodcast #HormoneInsight #CME #MedTwitter #DoctorsOfYouTube #EvidenceBasedMedicine #Tirzepatide #Semaglutide

The Week in Diabetes & Endocrinology — Episode 003 | April 17, 2026

From Hormone Insight (hormoneinsight.com)

Six stories this week that endocrinologists, diabetologists, and internists need to know.

TIMESTAMPS:

0:00 — Introduction & This Week's Stories

1:15 — Automated Insulin Delivery in Type 2 Diabetes: A Landmark Trial Worth Unpacking

5:30 — Enlicitide: The First Oral PCSK9 Inhibitor (CORALreef Lipids)

9:30 — SCORED and Sotagliflozin: What the Trial Actually Tells Us

12:30 — Semaglutide in Type 1 Diabetes + Obesity (NEJM Evidence)

15:00 — Boehringer Ingelheim's Strategic Bet on Obesity + Liver Health

16:30 — Chronotype-Aligned Exercise: Timing May Matter as Much as Training

18:00 — Closing Thoughts

REFERENCES & SHOW NOTES:

▸ AID in T2D (NEJM, 2IQP trial): https://doi.org/10.1056/NEJMoa2415948

▸ Enlicitide CORALreef Lipids (Med): https://doi.org/10.1016/j.medj.2026.101097

▸ CORALreef Lipids primary (NEJM): https://doi.org/10.1056/NEJMoa2511774

▸ Semaglutide in T1D + obesity (NEJM Evidence): https://doi.org/10.1056/EVIDoa2500173

▸ Chronotype-aligned exercise RCT (Open Heart): https://doi.org/10.1136/openhrt-2025-003573

ABOUT THIS PODCAST:

A weekly evidence-based review of the top stories in diabetes, obesity, thyroid, and endocrinology — modeled on Medscape's "This Week in Cardiology." New episodes every Thursday. For healthcare professionals.

▸ Website: https://hormoneinsight.com

▸ Full show notes: https://hormoneinsight.com/podcast

DOWNLOAD THE APP:

▸ iOS: https://apps.apple.com/dz/app/hormone-insight/id6749515856

▸ Android: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl

️ This content is intended for healthcare professionals. It does not constitute medical advice for patients.

#Endocrinology #DiabetesResearch #AutomatedInsulinDelivery #PCSK9 #Enlicitide #Sotagliflozin #SCORED #Semaglutide #Type1Diabetes #Survodutide #Obesity #MASH #Chronotype #Exercise #MedicalPodcast #HormoneInsight #CME #MedTwitter #DoctorsOfYouTube #EvidenceBasedMedicine #Tirzepatide